The U.S. Therapeutic Oncology Market, 2003-2013:
Trends, Technologies & Opportunities

· 301 pages   · 60 Exhibits   · 86 Company Profiles   · Pub. Date September 2003   · Report #D101

This report is a detailed market and technology assessment and forecast of the products and technologies involved in therapeutic oncology. The report provides detailed incidence and prevalence data by cancer type, and their trends, describing the current and emerging practices in the clinical management of cancer. The report details the current and emerging products, technologies and markets involved in oncology encompassing detection & diagnostic systems, drug delivery devices, chemotherapy, ablation, orthotics & prosthetics, radiation therapy, biological therapies, pharmaceuticals, transplantation and emerging technologies. The report provides a current and forecast assessment of the U.S. markets for these technologies, with particular emphasis on the market impact of new technologies through the coming decade, profiles over 80 key companies in this industry detailing their current products, current market position and products under development.

Table of Contents

Executive Summary

Overview of the U.S. Oncology Market

Trends & Opportunities

Market Leaders

Section 1:        Clinical Background 

1.1       Angiogenesis Inhibitors

1.2       Apoptosis

1.3       Carcinogens

1.4       Lymph Nodes

1.5       Melanoma

1.6       Metastasis

1.7       Neuroblastomas

1.8       Oncogenes

1.9       Sarcomas

1.10     Staging Systems

1.10.1        Summary Staging

1.10.2        TNM Staging

1.11     Telomeres

1.12     Tumors

Section 2:        Disease States: Etiology, Incidence, Prevalence, Treatment Trends, Survival Rates  

2.1       Prostate Cancer

2.2       Breast Cancer

2.3       Lung Cancer

2.4       Colorectal Cancer

2.5       Lymphoma

2.6       Skin Cancer

2.7       Bladder Cancer

2.8       Kidney Cancer

2.9       Uterine Cancer

2.10     Pancreatic Cancer

2.11     Leukemia

2.12     Head & Neck Cancer

2.13     Oral Cavity and Pharynx

2.14     Ovarian Cancer

2.15     Cervical Cancer

2.16     Liver Cancer

2.17     Bone Cancer

Section 3:        Products & Technologies

3.1       Radiation Therapies

3.1.1          Brachytherapy

3.1.2          Stereotactic Radiosurgery

3.1.2.1       CyberKnife

3.1.2.2       Gamma Knife

3.2       Ablation Devices

3.2.1          Cryoablation

3.2.2          Hydraulic Ablation

3.2.3          RF Ablation

3.2.4          Ultrasound Ablation

3.2.5          Microwave Ablation

3.2.6          Thermal Ablation

3.3       Oncology Devices

3.3.1          Site-specific Delivery

3.3.1.1       MicroSyringes

3.3.2          Excision Devices

3.3.3          Subcutaneous Ports

3.3.4          Biopsy Needles

3.4       Imaging Systems

3.4.1          Fusion Imaging

3.4.2          Infrared Optical Coherence Tomography

3.4.3          Tomosynthesis

3.4.4          Magnetic Resonance Imaging (MRI)

3.4.5          Nanoparticles

3.4.6          Positron Emission Tomography (PET)

3.4.7          Computed Tomography (CT)

3.4.8          Microscopic Systems

3.4.9          White Light Endoscopy

3.5       Cancer BioPharmacology

3.5.1          Immunotherapy

3.5.1.1       MonoClonal Antibodies

3.5.1.2       Vasopermeation Enhancement Agents

3.5.1.3       Tumor Vaccines

3.5.1.4       Targeted Enzyme Therapies

3.5.1.4.1          Enzyme Inhibitors

3.5.2          AntiSense Therapy

3.5.3          Growth Factors

3.5.3.1       Antiangiogenic Agents

3.5.4          Gene Therapy

3.6       Other Technologies

3.6.1          Stem Cell Therapy

3.6.2          Bone Marrow Transplantations

3.6.3          Tumor Markers

3.6.4          Molecular Fingerprinting

3.6.5          Hepatic Chemoembolization

3.6.6          Hormonal Therapies

3.6.7          Synthetic Blood Substitute

3.6.8          Focused Heat

Section 4:        Therapeutic Oncology Products Market 

4.1       Cancer Biopharmacology

4.2       Radiation Therapies

4.2.1          Radiation Oncology Equipment

4.2.2          Brachytherapy Implant Therapy

4.3       Energy Ablation Systems

4.4       Oncology Therapy Devices

4.5       Market Leaders

Section 5:        Company Profiles 

5.1       Abbott Laboratories

5.2       Access Oncology

5.3       Acoustic MedSystems

5.4       Accuray

5.5       Abaxis

5.6       Affymetrix

5.7       Allos Therapeutics

5.8       AmeriPath

5.9       Amgen

5.10     AnorMED

5.11     Artemis Medical, Inc.

5.12     AstraZeneca

5.13     ATI Medical

5.14     Avenir

5.15     Aventis

5.16     AVI Biopharma

5.17     Baxter International

5.18     Bayer

5.19     Berlex

5.20     Beckman Coulter

5.21     Bioject

5.22     BioLuminate

5.23     Boston Scientific Oncology

5.24     Bristol Myers Squibb Oncology

5.25     CancerVax

5.26     CellExSys

5.27     Celsion

5.28     CeMines

5.29     Computerized Thermal Imaging

5.30     Corgentech

5.31     CR Bard

5.32     Cytogen

5.33     Cytyc

5.34     EDAP

5.35     Dendreon

5.36     EndoBionics

5.37     Endocare

5.38     Endo Pharmaceuticals

5.39     EORTC

5.40     ERBE USA

5.41     Focus Surgery

5.42     GE Medical

5.43     Genentech

5.44     Genta

5.45     Genzyme

5.46     GlaxoSmithKline

5.47     GlycoGenesys

5.48     Horizon Medical Products

5.49     Johnson & Johnson

5.50     IDEC

5.51     ILEX

5.52     Imalux

5.53     Image Guided Neurologics

5.54     Imagyn

5.55     Imclone

5.56     Immunomedics

5.57     Immuno-Designed Molecules

5.58     Implant Sciences

5.59     Introgen Therapeutics

5.60     Light Sciences Corporation

5.61     Lorus Therapeutics

5.62     McKinley Medical

5.63     Mentor

5.64     MGI Pharma

5.65     Millennium Pharmaceuticals

5.66     Neopharm

5.67     Neothermia

5.68     Northwest Biotherapeutics

5.69     Novartis Oncology

5.70     NTI

5.71     OSI Pharmaceuticals

5.72     Peregrine Pharmaceuticals

5.73     Pfizer Pharmacia Oncology

5.74     PRAECIS Pharmaceuticals

5.75     Precision Therapeutics

5.76     Prosurg

5.77     Proxima Therapeutics

5.78     Roche Oncology

5.79     Sanofi-Synthelabo

5.80     SIRTeX

5.81     SuperGen, Inc.

5.82     Targeted Diagnostics & Therapeutics

5.83     Theragenics

5.84     Titan Pharmaceuticals

5.85     Varian Medical Systems

5.86     Xillix Technologies

Appendix: List of Companies

List of Exhibits

Exhibit ES-1:  High Growth Segments in Therapeutic Oncology

Exhibit ES-2:  U.S. Oncology Market Opportunity, 2003-2013

Exhibit ES-3:  Targeted Cancer Therapies

Exhibit ES-4:  Oncology Therapeutics Market Share Leaders

Exhibit 1-1:  Cancer Summary Staging

Exhibit 1-2:  Tumor Size Designations

Exhibit 1-3:  Extent of Spread to Palpable Node

Exhibit 1-4:  Degree of Metastasis

Exhibit 2-1:  Causes of the 2.4 Million Annual Deaths in the U.S.

Exhibit 2-2:  2003 Cost of Cancer to the U.S. Economy

Exhibit 2-3a:  Probability of Developing Cancers in the U.S. (tabular)

Exhibit 2-3b:  Probability of Developing Cancers in the U.S. (graphic)

Exhibit 2-4:  2003 Estimated New Cases of Cancer in the U.S.

Exhibit 2-5:  2003 Cancer Deaths in the U.S.

Exhibit 2-6:  2003 Cancer Incidence and Mortality by System

Exhibit 2-7:  U.S. Prostate Cancer Survival Rates 2003

Exhibit 2-8:  Non-Drug Treatment Options for Prostate Cancer

Exhibit 2-9:  Staging Breast Cancer

Exhibit 2-10:  Five-Year Breast Cancer Survival Rate

Exhibit 2-11:  2003 U.S. Lung Cancer Survival Rates

Exhibit 2-12:  Survival Rates for Colorectal Cancer

Exhibit 2-13:  U.S. 2003 Survival Rates for Lymphoma

Exhibit 2-14:  Bladder Cancer 2003 U.S. Survival Rates

Exhibit 2-15:  U.S. Kidney Cancer Survival Rates 2003

Exhibit 2-16:  U.S. 2003 Endometrial Cancer Survival Rates

Exhibit 2-17:  U.S. Pancreatic Cancer Survival Rates 2003

Exhibit 2-18:  U.S. 2003 Leukemia Survival Rates

Exhibit 2-19:  U.S. 2003 Head & Neck Cancer Survival Rates

Exhibit 2-20:  U.S. 2003 Oral Cancer Survival Rate

Exhibit 2-21:  U.S. Ovarian Cancer Survival Rates 2003

Exhibit 2-22:  U.S. 2003 Survival Rates Cervical Cancer

Exhibit 2-23:  U.S. Liver Cancer Survival Rates 2003

Exhibit 2-24:  U.S. 2003 5 Year Survival Rates Bone Cancer

Exhibit 3-1:  Brachytherapy Radioactive Seed Products

Exhibit 3-2:  Subcutaneous Infusion Ports

Exhibit 3-3:  Top Approved Cancer Therapeutics

Exhibit 3-4:  Targeted Cancer Therapies, By Company

Exhibit 3-5:  Epidermal Growth Factor Receptor Inhibitors (EGFR)

Exhibit 4-1:  2003 Cost of Cancer to the U.S. Economy

Exhibit 4-2:  U.S.  Oncology Market Opportunity by Segment, 2003-2013

Exhibit 4-3:  NDAs Originating from BioPharma Collaborations

Exhibit 4-4:  U.S. Biopharmacology Market, 2003-2013

Exhibit 4-5:  U.S. Radiation Oncology Equipment Market, 2003-2013

Exhibit 4-6:  U.S. Brachytherapy Implant Market, 2003-2013

Exhibit 4-7:  U.S. Tumor Ablation Systems Market, 2003-2013

Exhibit 4-8:  U.S. Oncology Therapy Devices Market, 2003-2013

Exhibit 4-9:  Oncology Therapeutics Market Share Leaders

Exhibit 4-10:  Major Cancer Segment Focus by Company

Exhibit 4-11:  Top Market Share Holders by Major Cancer Segment

Exhibit 5-1:  Access Oncology Proprietary Product Portfolio

Exhibit 5-2:  Allos Therapeutics Product Pipeline

Exhibit 5-3:  Amgen Oncology R&D Pipeline

Exhibit 5-4:  AstraZeneca 2002 Oncology Product Sales

Exhibit 5-5:  AstraZeneca 2003 R&D Cancer Therapeutic Pipeline

Exhibit 5-6:  Genta Oncology Pipeline

Exhibit 5-7:  GlaxoSmithKline R&D Pipeline

Exhibit 5-8:  Immunomedics Potential Imaging-Therapy Products

Exhibit 5-9:  Introgen Oncology Product Development

Exhibit 5-10:  Novartis Oncology Products

Exhibit 5-11:  Pfizer Pharmacia Oncology Sales Q1-Q2 2003

Exhibit 5-12:  Roche Oncology Sales 2002